Endocyte

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases.

Our vision is to make precision medicine available to physicians and patients for the treatment of cancers and other difficult-to-treat diseases.



We are working to provide clinicians with an accurate and improved way to select the patients who may receive the greatest benefit from a particular therapy. Because our values are founded on improving the health of patients, we strive to achieve targeted drug delivery to diseased cells to improve effectiveness of therapy and reduce undesirable side effects.

Type
Public
HQ
West Lafayette, US
Founded
1995
Size (employees)
78 (est)
Endocyte was founded in 1995 and is headquartered in West Lafayette, US

Key People at Endocyte

Ron Ellis

Ron Ellis

President & CEO
Mike A. Sherman

Mike A. Sherman

CFO

Endocyte Office Locations

Endocyte has office in West Lafayette
West Lafayette, US

Endocyte Metrics

Endocyte Summary

Market capitalization

$87.5 M

Closing share price

$2.09
Endocyte's current market capitalization is $87.5 M.

Endocyte Financials

Endocyte's revenue is $70 K in FY, 2015 which is a 99.9% decrease from the previous period.
FY, 2015FY, 2014FY, 2013

Revenue

$70 K$70.4 M$64.9 M

Net Income

$-41.3 M$5.46 M$-18 M

Endocyte Market Value History

Endocyte Company Life

You may also be interested in